v3.26.1
Stockholders' Equity
3 Months Ended
Mar. 31, 2026
Stockholders Equity Note [Abstract]  
Stockholders' Equity

NOTE 9 – STOCKHOLDERS’ EQUITY

 

The Company’s amended and restated certificate of incorporation, filed with the Delaware Secretary of State on February 2, 2018, authorizes the Company to issue 10,000,000 shares of preferred stock and 50,000,000 shares of common stock.

 

2017 Equity Incentive Plan

 

On October 10, 2017, the Company’s board of directors approved and adopted the Company’s 2017 Equity Incentive Plan (as amended to date, the “2017 Plan”), subject to stockholder approval thereof. On December 18, 2017, the Company’s stockholders approved the 2017 Plan. The 2017 Plan allows for the grant of a variety of equity vehicles to provide flexibility in the grant and issuance of equity awards, including stock options, unrestricted stock grants, restricted stock units (“RSUs”), stock bonuses and performance-based awards. An aggregate of 1,500,000 shares of common stock were initially reserved for issuance under the 2017 Plan. The number of shares authorized for issuance under the 2017 Plan was increased to 3,000,000 shares on May 19, 2021 and further increased to 5,000,000 shares on May 15, 2024.

 

As of March 31, 2026, 670,255 shares remain available for future issuance under the 2017 Plan.

 

Executive Employment Agreements

On June 5, 2023, in connection with, and as a material inducement to, the appointment of Michael Knowles as the Company’s new chief executive officer and president, Mr. Knowles was granted (i) non-qualified stock options to purchase 400,000 shares of Company common stock (the “Inducement Options”), which Inducement Options

have an exercise price equal to $2.95 per share and will expire ten years from the date of the grant; and (ii) 400,000 restricted stock units (together with the Inducement Options, the “Inducement Grants”).

Both of the Inducement Grants shall vest over a four-year period as follows: 25% on the one-year anniversary of the date of the grant, and the remaining 75% will vest in six equal installments, commencing six months after the one-year anniversary of the date of grant and every six months thereafter until fully vested, subject to Mr. Knowles’ continued employment by the Company.

The Inducement Grants were granted outside of the Company’s 2017 Plan and any other equity incentive plans, and in reliance on the employment inducement exemption provided under the Nasdaq Listing Rule 5635(c)(4).

Stock Options

A summary of stock option activity under the Company’s current equity incentive plans during the three month period ended March 31, 2026, was as follows:

 

 

 

Stock Options Outstanding

 

 

 

Number of
Underlying Shares

 

 

Weighted
Average
Exercise
Price

 

 

Weighted
Average
Remaining
Contractual
Life (in years)

 

 

Aggregate
Intrinsic
Value

 

Outstanding on January 1, 2026

 

 

621,539

 

 

$

2.81

 

 

 

5.37

 

 

$

3,004,897

 

Granted

 

 

-

 

 

$

-

 

 

 

-

 

 

 

-

 

Forfeited / Canceled

 

 

-

 

 

$

-

 

 

 

-

 

 

 

-

 

Exercised

 

 

(15,313

)

 

$

3.05

 

 

 

-

 

 

$

(69,174

)

Outstanding on March 31, 2026

 

 

606,226

 

 

$

2.81

 

 

 

5.23

 

 

$

2,935,723

 

Exercisable as of March 31, 2026

 

 

456,226

 

 

$

2.76

 

 

 

4.60

 

 

$

2,242,723

 

 

As of March 31, 2026, there was $235,003 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 0.59 years.

 

There were no options granted during the three month periods ended March 31, 2026 and 2025. The following table presents the grant date fair value of options vested and the intrinsic value of options exercised:

 

 

 

For the Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

Grant date fair value of options vested

 

$

734,604

 

 

$

931,460

 

Intrinsic value of options exercised

 

$

106,890

 

 

$

233,850

 

 

 

 

 

 

 

If there are any modifications or cancellations of the underlying unvested awards, the Company may be required to accelerate, increase, or cancel any remaining unearned stock-based compensation expense or calculate and record additional expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that the Company grants additional common stock options or other stock-based awards.

Restricted Stock Units

RSUs may be granted at the discretion of the compensation committee of the Company's board of directors under the 2017 Plan in connection with the hiring and retention of personnel and are subject to certain conditions. RSUs generally vest quarterly or semi-annually over a period of one to three years and are typically forfeited if employment is terminated before the RSUs vest. The compensation expense related to the RSUs is calculated as the fair value of the common stock on the grant date and is amortized to expense over the vesting period and is adjusted for estimated forfeitures.

The Company’s RSU activity for the three months ended March 31, 2026, was as follows:

 

 

 

Restricted Stock Units

 

 

 

Number of
Underlying Shares

 

 

Weighted
Average Grant
Date Fair Value

 

Unvested on January 1, 2026

 

 

997,647

 

 

$

3.32

 

Granted

 

 

429,366

 

 

$

9.66

 

Vested

 

 

(259,165

)

 

$

3.46

 

Canceled

 

 

(23,235

)

 

$

2.78

 

Unvested on March 31, 2026

 

 

1,144,613

 

 

$

5.68

 

 

As of March 31, 2026, there was $5,872,202 of unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted average period of 1.23 years.

Stock-based compensation expense associated with continuing operations for the three month periods ended March 31, 2026 and 2025, was comprised of the following:

 

 

 

For the Three Months Ended March 31,

 

Stock-based compensation classified as:

 

2026

 

 

2025

 

General and administrative

 

$

405,360

 

 

$

408,246

 

Production

 

 

39,440

 

 

 

21,421

 

Marketing and selling

 

 

145,437

 

 

 

91,770

 

Research and development

 

 

64,891

 

 

 

56,968

 

 

 

$

655,128

 

 

$

578,405

 

 

Stock-based compensation expense associated with discontinued operations for the three month periods ended March 31, 2026 and 2025 was $0 and $34,156, respectively.

 

Warrants

 

The Company did not have any outstanding warrants as of March 31, 2026 or December 31, 2025.